NasdaqGS · Medical Care Facilities

Compass Pathways (CMPS)

Stock, pipeline and biotech catalyst intelligence

Analyst view

Strong Buy+78.2%

$23.75 average target

$13.33-0.49 (-3.5%)Latest market snapshot · Yahoo Finance

Market cap$1.85B

Cash$433.3M

Quarterly burn$40.3M

Pipeline assets3

Short float10.0%

Market expectations

Analyst Ratings & Price Targets

Data may be delayed

Street view at a glance

The average target implies 78.2% upsideTargets are estimates—not guarantees—and can change after company updates.

$23.75Average target

Wall Street consensus

Strong BuyBased on 16 analyst opinions

16ratings

Buy 15Hold 1Sell 0

Price-target range

$23.75

+78.2%

Low $13.00High $65.00

CurrentAverage

Bear case$13.00-2.5%

Base case$23.75+78.2%

Bull case$65.00+387.6%

Analyst coverage16published opinions

Bullish share94%buy recommendations

Target spread$52low-to-high dispersion

Consensus score1.31.0 is strongest

Recommendation mix

Current rating breakdown

16 tracked ratings

Company profile

About Compass Pathways

COMPASS Pathways plc operates as a biotechnology company that focuses on mental health in the United Kingdom and the United States. The company develops COMP360, a psilocybin therapy, which is in Phase III clinical trial for the treatment of treatment-resistant depression; and is in Phase II clinical trial for treating post-traumatic stress disorder and anorexia nervosa. The company was formerly known as COMPASS Rx Limited and changed its name to COMPASS Pathways plc in August 2020. The company was incorporated in 2020 and is headquartered in London, the United Kingdom.

Company profile supplied by Yahoo Finance. Catalyst dates can change and should be confirmed against the linked primary source.

Page updated Aug 21, 2026 · Yahoo quotes cached for one minute; reference data may be used when a live field is unavailable.